TAKHZYRO Drug Profile

✉ Email this page to a colleague

Summary for Tradename: TAKHZYRO

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for TAKHZYRO

Recent Clinical Trials for TAKHZYRO

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
St Vincent's Institute of Medical Research	Phase 1
Takeda	Phase 3

See all TAKHZYRO clinical trials

Pharmacology for TAKHZYRO

Mechanism of Action	Kallikrein Inhibitors
Established Pharmacologic Class	Plasma Kallikrein Inhibitor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for TAKHZYRO Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for TAKHZYRO Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for TAKHZYRO Derived from Patent Text Search

No patents found based on company disclosures

Last updated: September 8, 2026

Takhzyro is a commercially durable biologic for hereditary angioedema (HAE), with revenue growth driven by conversion from older plasma-derived prophylaxis, expanded use in adolescents, and continued uptake of less frequent dosing. Takeda’s principal risk is not near-term generic erosion. The main medium-term risks are competition from oral prophylaxis, newer kallikrein inhibitors, payer pressure, and eventual biosimilar entry after U.S. biologic exclusivity expires in 2030.

Takhzyro Market Dynamics, Revenue Growth, Patent Protection, and Generic Risk

What is Takhzyro and how does it work?

Takhzyro is the brand name for lanadelumab-flyo, a fully human monoclonal antibody developed to prevent attacks of hereditary angioedema. Takeda markets the product globally after acquiring Shire, which had acquired Dyax and its lanadelumab program.

Lanadelumab binds and inhibits plasma kallikrein. This reduces bradykinin generation, the principal mediator of vascular leakage in HAE attacks.

Attribute	Takhzyro
Active ingredient	Lanadelumab-flyo
Product class	Fully human monoclonal antibody
Target	Plasma kallikrein
Primary indication	Routine prevention of HAE attacks
U.S. approval	August 23, 2018
Original developer	Dyax
Current commercial owner	Takeda
U.S. formulation	Subcutaneous injection
Standard adult/adolescent dosing	300 mg every two weeks; monthly dosing may be used in selected patients
U.S. pediatric expansion	Approved for patients aged 2 years and older
Main therapeutic alternatives	Haegarda, Cinryze, Orladeyo, Firazyr, Berinert, Ruconest

Takhzyro is used for prophylaxis rather than acute treatment. Patients still require an on-demand therapy for breakthrough attacks.

How large is the Takhzyro market?

Takhzyro operates in a rare-disease market with high treatment persistence and limited patient switching. HAE affects an estimated 1 in 50,000 people, producing a small patient population but high annual treatment costs.

The commercial market has expanded for three reasons:

More HAE patients are being diagnosed and treated.
Patients are moving from intravenous or plasma-derived prophylaxis to subcutaneous biologics.
Long-term prophylaxis is being used more broadly, including in patients who previously relied mainly on acute treatment.

Takhzyro competes in a global HAE prophylaxis market that includes injectable and oral products. The product’s most direct competitors are Haegarda, a subcutaneous C1-esterase inhibitor, and Orladeyo, an oral plasma kallikrein inhibitor marketed by BioCryst.

Takhzyro’s market position

Takhzyro has a strong position in patients who prioritize attack reduction, infrequent administration, and a non-plasma-derived therapy. Its principal commercial disadvantages are injection burden, high price, and competition from oral treatment.

Orladeyo is the most important differentiated competitor because it provides oral prophylaxis. Its advantages are convenience and avoidance of injections. Takhzyro retains advantages in clinical familiarity, long-term market presence, and strong physician experience.

Product	Company	Mechanism	Administration	Commercial implication
Takhzyro	Takeda	Plasma kallikrein antibody	Subcutaneous	Established biologic prophylaxis leader
Haegarda	CSL Behring	C1-esterase inhibitor replacement	Subcutaneous	Plasma-derived alternative
Orladeyo	BioCryst	Oral plasma kallikrein inhibitor	Oral daily dosing	Main convenience-driven competitor
Cinryze	Takeda	C1-esterase inhibitor replacement	Intravenous	Older prophylaxis option
Firazyr	Takeda	Bradykinin B2 receptor antagonist	Subcutaneous as needed	Acute attack treatment
Berinert	CSL Behring	C1-esterase inhibitor replacement	Intravenous or subcutaneous	Acute treatment and prophylaxis in selected markets
Ruconest	Pharming	Recombinant C1-esterase inhibitor	Intravenous	Acute treatment

What has been Takhzyro’s revenue trajectory?

Takeda does not report Takhzyro as a separately listed public company, but identifies it as a key growth product in its annual filings. Reported sales have increased substantially since launch.

Takeda fiscal year ended March 31	Approximate Takhzyro sales	Commercial trend
FY2019	¥20 billion to ¥30 billion	Initial launch period
FY2020	More than ¥60 billion	Rapid U.S. and European uptake
FY2021	Approximately ¥85 billion to ¥95 billion	Continued prophylaxis conversion
FY2022	Approximately ¥115 billion to ¥125 billion	Broader geographic penetration
FY2023	Approximately ¥130 billion to ¥145 billion	Mature growth-product expansion
FY2024	Approximately ¥145 billion to ¥160 billion	Continued volume growth, with currency effects

The exact yen value changes with Takeda’s reporting classification and foreign-exchange translation. The direction is clear: Takhzyro has moved from launch-stage revenue into Takeda’s group of established growth products.

The revenue profile is attractive because HAE prophylaxis is chronic. Once a patient begins effective preventive therapy, discontinuation rates are generally lower than in acute-care drug categories. The product also benefits from recurring prescription volume rather than one-time treatment cycles.

What is driving Takhzyro revenue growth?

Volume has been the primary growth driver. Takeda has benefited from:

Increased diagnosis of HAE.
Broader use of prophylaxis.
Switching from intravenous C1-esterase inhibitor products.
Expansion into pediatric patients.
Greater use of home administration.
Growth in Europe, Japan, and other international markets.
Retention of patients who respond adequately to treatment.

Price increases and foreign-exchange movements have influenced reported revenue, but the underlying commercial case depends primarily on treated-patient growth and persistence.

When does Takhzyro lose U.S. exclusivity?

Takhzyro’s U.S. biologic reference-product exclusivity expires on August 23, 2030, based on the 12-year exclusivity period applicable to reference biologics approved under the Public Health Service Act.

The exclusivity date does not necessarily equal the first possible biosimilar launch date. A biosimilar applicant may file an abbreviated biologics license application before that date, and patent disputes can delay or accelerate market entry depending on litigation and settlement terms.

U.S. milestone	Date
FDA approval	August 23, 2018
Reference biologic exclusivity	August 23, 2030
Potential biosimilar preparation period	Before 2030
Earliest practical competitive entry	Dependent on patents, litigation, and settlements

In Europe, regulatory data and market protection generally follows the 8+2+1 framework, although the practical entry date depends on the applicable authorization, supplementary protection certificates, national enforcement, and patent coverage.

What patents protect Takhzyro?

Takhzyro is protected through a layered patent estate covering the antibody, binding characteristics, therapeutic use, dosing, formulations, and manufacturing-related technology. The most commercially important claims are expected to concern:

Antibodies that bind plasma kallikrein.
Specific antibody sequences and variants.
Use of lanadelumab to prevent HAE attacks.
Subcutaneous dosing regimens.
Reduced-frequency dosing.
Pharmaceutical compositions and stabilizing formulations.
Cell lines, expression systems, and production methods.

Because Takhzyro is a biologic, its patent strategy is different from that of a conventional small-molecule drug. A biosimilar applicant does not need to reproduce every manufacturing step, but the reference sponsor can assert patents covering the antibody molecule, formulation, method of treatment, and manufacturing process.

How strong is the Takhzyro patent estate?

The estate is commercially meaningful but does not eliminate long-term biosimilar risk. The strongest protection is likely to come from composition-of-matter and antibody sequence claims. Method-of-use and dosing patents can add leverage, but their value depends on claim scope, validity, infringement evidence, and the design of a competing label.

Formulation and manufacturing patents may be useful in settlement negotiations. They are less likely to block all biosimilar competition if an applicant can develop a non-infringing formulation or process.

The practical protection period may extend beyond the 2030 biologic exclusivity date through patents, but the effective duration cannot be determined from regulatory exclusivity alone.

Is Takhzyro listed in the Orange Book?

No. Takhzyro is a biologic, not a conventional small-molecule drug, so its principal U.S. reference is the FDA’s Purple Book rather than the Orange Book.

The Hatch-Waxman Paragraph IV framework applies to abbreviated new drug applications for small molecules. Biosimilar applicants use the Public Health Service Act pathway under Section 351(k). As a result:

Takhzyro does not face a conventional Paragraph IV generic challenge.
A biosimilar applicant may provide a patent dance notice under the Biologics Price Competition and Innovation Act.
Patent disputes may proceed in federal court under the BPCIA framework.
The absence of an Orange Book listing does not mean the product lacks enforceable patents.

What biosimilar risk does Takhzyro face?

No widely established U.S. biosimilar competitor to lanadelumab had reached the market through mid-2024. The first competitive threat is more likely to come from branded alternatives and oral inhibitors than from an immediate biosimilar launch.

A lanadelumab biosimilar would face several development barriers:

Complex monoclonal-antibody analytical comparability.
Need to demonstrate similarity in pharmacokinetics and immunogenicity.
Manufacturing scale and quality-control requirements.
Limited patient numbers in HAE clinical trials.
Patent litigation over antibody, dosing, formulation, and manufacturing claims.
Payer and physician requirements for switching a stable patient.

The commercial impact of a biosimilar would likely be gradual rather than immediate. Rare-disease physicians often value treatment continuity, and insurers may use formulary incentives rather than automatic substitution. Discounts could still be material, particularly for new patients and government-supported channels.

Which companies are challenging Takhzyro commercially?

The most important competitive companies are:

BioCryst Pharmaceuticals, with Orladeyo.
CSL Behring, with Haegarda, Berinert, and related C1-esterase inhibitor products.
Pharming Group, with Ruconest.
Takeda itself, through Cinryze and acute-treatment products such as Firazyr.

BioCryst poses the clearest strategic challenge because Orladeyo competes for the same chronic prophylaxis population while offering oral administration. CSL Behring has a broad HAE franchise and can cross-sell prophylaxis and acute-treatment products. Takeda’s own portfolio creates both a competitive advantage and a risk of internal cannibalization between Takhzyro and older products.

What is Takhzyro’s FDA and regulatory status?

Takhzyro is FDA-approved for routine prophylaxis to prevent attacks of HAE in patients aged 2 years and older. The product is also approved in major international markets, including the European Union, for prevention of recurrent HAE attacks in eligible patients.

The major regulatory assets are:

Established safety and efficacy data in a rare disease.
Pediatric labeling.
Home-injection suitability.
Less frequent dosing than daily oral prophylaxis.
Broad physician familiarity after several years of commercial use.

Regulatory risk is therefore lower than development-stage risk. The principal regulatory issues are post-marketing safety, immunogenicity monitoring, manufacturing consistency, and label expansion. A future competitor may seek approval based on clinical data designed to show similarity or non-inferiority rather than reproduce the entire Takhzyro development program.

What litigation and settlement risks affect Takhzyro?

A conventional Paragraph IV litigation wave is not expected because Takhzyro is a biologic. The relevant risk is BPCIA litigation involving a biosimilar applicant and Takeda.

Potential disputes would likely focus on:

Antibody sequence claims.
Plasma kallikrein binding claims.
Dosing frequency.
HAE prevention methods.
Formulation claims.
Manufacturing and cell-line patents.

A settlement could permit biosimilar entry before the last asserted patent expires. The terms could include a licensed entry date, supply arrangements, or restrictions on launch timing. Public visibility into these agreements may be limited.

No major publicly established Takhzyro biosimilar settlement had materially changed the product’s U.S. competitive position through mid-2024.

How does Takhzyro compare with Orladeyo?

Takhzyro has the stronger legacy position and a longer commercial record. Orladeyo has the administration advantage because it is oral.

Factor	Takhzyro	Orladeyo
Company	Takeda	BioCryst
Mechanism	Monoclonal antibody against plasma kallikrein	Oral plasma kallikrein inhibitor
Administration	Subcutaneous	Oral
Dosing convenience	Every two weeks or monthly in selected patients	Daily
Market maturity	Earlier launch and broader installed base	Newer challenger
Key advantage	Established efficacy and infrequent dosing	No injection
Main risk	Injection burden and eventual biosimilar exposure	Daily dosing and competitive market access

The competitive outcome will depend heavily on patient preference, payer coverage, treatment response, and physician confidence. Takhzyro is likely to retain patients who value less frequent dosing and established biologic efficacy. Orladeyo is positioned to win patients who prioritize oral treatment.

What revenue is exposed to generic or biosimilar entry?

Takhzyro revenue has become strategically important to Takeda, but it remains smaller than the company’s largest products, including Entyvio. The product is exposed to a concentrated rare-disease market, which limits patient volume but supports high revenue per treated patient.

The commercial risk profile is staged:

Period	Primary risk
Through 2027	Branded competition and payer controls
2028-2030	Pre-biosimilar contracting and patent litigation
From 2030	Reference-product exclusivity ends in the U.S.
After 2030	Biosimilar entry, price erosion, and patient switching
Long term	Oral prophylaxis and next-generation kallikrein inhibitors

A reasonable launch scenario is continued growth before 2030, followed by slower growth as payers prepare for biosimilars and branded alternatives gain share. After entry, erosion is likely to be slower than for many small molecules because of biologic manufacturing complexity, rare-disease prescribing concentration, and limited interchangeability.

What is the outlook for Takhzyro?

Takhzyro should remain a major HAE product through the second half of the 2020s. Its strongest commercial assets are established clinical use, recurring prophylaxis demand, broad regulatory coverage, and a dosing schedule that is more convenient than daily oral therapy for some patients.

The main headwinds are Orladeyo’s oral format, possible new HAE therapies, payer pressure, and the eventual end of U.S. biologic exclusivity. Takeda’s ability to preserve revenue will depend on pediatric and geographic expansion, patient retention, manufacturing reliability, and contracting before biosimilar competition emerges.

Key Takeaways

Takhzyro is Takeda’s lanadelumab biologic for routine prevention of HAE attacks.
U.S. approval occurred on August 23, 2018, with 12-year reference-product exclusivity extending to August 23, 2030.
Revenue has grown from launch-stage sales to roughly ¥150 billion annually on Takeda’s fiscal-year reporting basis.
The principal current competitor is BioCryst’s oral plasma kallikrein inhibitor Orladeyo.
Takhzyro is not listed in the Orange Book because it is a biologic; the relevant framework is the Purple Book and BPCIA.
No conventional Paragraph IV generic challenge applies.
Long-term risk comes from biosimilar lanadelumab, oral prophylaxis, payer pressure, and patent litigation.
The product’s patent estate likely includes antibody, method-of-use, dosing, formulation, and manufacturing claims.
Takhzyro’s revenue outlook remains positive before 2030, with greater erosion risk after biosimilar entry.

FAQs

Can a generic drug replace Takhzyro?

No conventional generic can replace Takhzyro through an ANDA. A competing manufacturer would need to pursue the FDA’s 351(k) biosimilar pathway or develop a separate HAE therapy.

Is Takhzyro interchangeable with a future biosimilar?

Interchangeability would require a separate FDA determination. A biosimilar may be approved without being designated interchangeable, limiting automatic pharmacy substitution.

Does Orladeyo threaten Takhzyro sales?

Yes. Orladeyo competes directly for chronic HAE prophylaxis patients and has an oral-administration advantage. Takhzyro retains advantages in dosing frequency, clinical experience, and established physician use.

Does Takhzyro have orphan-drug protection?

Takhzyro received orphan-drug designation for HAE. Orphan-drug exclusivity is separate from biologic reference-product exclusivity and does not prevent all competing therapies if they meet the applicable regulatory standard.

What is the biggest long-term risk to Takhzyro?

The largest long-term risk is cumulative rather than singular: oral prophylaxis competition before 2030, followed by biosimilar and price pressure after U.S. biologic exclusivity expires.

References

BioCryst Pharmaceuticals, Inc. (2024). 2023 annual report.
CSL Behring. (2024). Haegarda and Berinert prescribing information.
Food and Drug Administration. (2018). Takhzyro (lanadelumab-flyo) prescribing information. U.S. Department of Health and Human Services.
Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. U.S. Department of Health and Human Services.
Takeda Pharmaceutical Company Limited. (2020). Annual report 2019.
Takeda Pharmaceutical Company Limited. (2022). Annual report 2021.
Takeda Pharmaceutical Company Limited. (2023). Annual report 2022.
Takeda Pharmaceutical Company Limited. (2024). Annual report 2023.
U.S. Congress. (2010). Biologics Price Competition and Innovation Act of 2009, Pub. L. No. 111-148, §§ 7001-7002.
European Medicines Agency. (2024). Takhzyro: EPAR product information.

More… ↓

⤷ Start Trial